News Article | May 4, 2017
(New York, NY - May 4, 2017) -- Immunotherapy, which has achieved remarkable results in late-stage lung cancer patients, can also hold great hope for newly diagnosed patients, cutting the deadly disease off before it has the chance to take hold and offering a potential cure, according to a new Mount Sinai study published today in Cell. Researchers at The Tisch Cancer Institute at Mount Sinai discovered that some of the same immune cells that allow immunotherapy to turn around some late-stage lung cancers are also present just as the disease takes hold. Before now, little was known about the immune response in early lung cancer, said Miriam Merad, MD, PhD, Professor of Oncological Sciences and of Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at Mount Sinai. Dr. Merad and a multidisciplinary team of thoracic surgeons, pathologists, and scientists devised a comprehensive study that began when patients went into surgery to have cancerous lesions removed. The patients' lung tumor samples, samples of surrounding healthy lung tissue, and blood samples were immediately analyzed on a cellular level to map out the immune system components present. The team of researchers crafted a barcoding method that attaches cells in each sample to a different metal isotope, allowing the samples to be pooled for a simultaneous analysis of cells from all three tissue types. The scientists combined this barcoding approach with high-dimensional profiling to map the complete immune landscape to search for tumor-driven changes that would be vulnerable to targeted immunotherapy. The analysis of the samples showed that stage I lung cancer lesions already harbor immune system components that likely compromise anti-tumor T cells' ability to fend off cancer. These single-cell analyses offered unprecedented detail of tumor-driven immune changes, providing a powerful tool for the future design of immunotherapies such as checkpoint inhibitors, particularly those that target the PD-1 and PD-L1 proteins that shield cancer from the immune system; these checkpoint inhibitors have shown great promise in later-stage cancers. "Immunotherapy has mostly been used in advanced or metastatic lung cancer, but its benefit in early-stage tumors remains unknown," Dr. Merad said. "The standard treatment for early lung cancer is normally surgical removal of the lesions--sometimes with chemotherapy and radiation. Our study reveals that early lung lesions are heavily infiltrated with many different immune cells, suggesting that immunotherapy could also work on very early lesions and potentially lead to a cure by heading cancer off at the pass before it really takes root in the lungs." This new research also identified a multitude of additional immunotherapy targets to increase the number of patients that would significantly benefit from immunotherapy, which at the moment remains fairly small. This research is being used to develop immunotherapy trials with early lung cancer patients. "About 50 percent of patients with small lung cancer lesions relapse," Merad said. "And when lung cancer is advanced, chemotherapy does not have a great success rate, so knowing how to attack the cancer at an early stage could have huge impacts on the number of patients relapsing and their overall survival. Our research further corroborates the belief that immunotherapy agents are most efficient at early stages of cancer, particularly in patients who have never been treated with chemotherapy." Raja M. Flores, MD, Chair of the Department of Thoracic Surgery at Mount Sinai Health System, and his team contributed significantly to the study by identifying patients and providing their tissue samples. Mount Sinai's Human Immune Monitoring Center (HIMC) also played an integral role, by providing a platform to analyze patient samples using quality control assays and cutting-edge technology. Through the HIMC, Dr. Merad plans to build a portal to share the results of this study and of other HIMC research to collaborate with colleagues at other cancer centers in the hopes of promoting further cancer and immunology research. This study was funded by Foundation pour la Recherche Medicale DEA20150633125 and NIH grants R01, R01 CA173861, U19AI128949, U24 AI 118644, U19 AI 117873-01. The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community-based facilities to tertiary and quaternary care. The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is on the "Honor Roll" of best hospitals in America, ranked No. 15 nationally in the 2016-2017 "Best Hospitals" issue of U.S. News & World Report. The Mount Sinai Hospital is also ranked as one of the nation's top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke's, and Mount Sinai West are ranked regionally. Mount Sinai's Kravis Children's Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in "Best Children's Hospitals." For more information, visit http://www. or find Mount Sinai on Facebook, Twitter and YouTube.
News Article | May 1, 2017
A new study out of Hyogo, Japan suggests that mesothelioma patients who relapse after extrapleural pneumonectomy (EPP) surgery may extend their survival with additional rounds of chemotherapy. Surviving Mesothelioma has just posted news of the report on its website. Click here to read the details. The Hyogo College of Medicine study focused on 39 patients with malignant mesothelioma whose cancer started growing again in the months after they had lung-removing EPP surgery. The median time to relapse was just under a year. According to the study in the International Journal of Clinical Oncology, mesothelioma patients who underwent additional chemotherapy after relapse experienced better outcomes. “The median survival time after EPP was significantly longer in 21 patients who received additional chemotherapy than in 18 patients who did not,” says Dr. Teruhisa Takuwa with Department of Thoracic Surgery at Hyogo College of Medicine. “The treatment path is not always clear for mesothelioma patients after first-line therapy fails, since there is no universally-accepted second-line treatment” says Alex Strauss, Managing Editor for Surviving Mesothelioma. “With median mesothelioma survival times more than three years after surgery, this study suggests that there is reason to hope, even after relapse.” To read the details of the new study including a comparison of survival times between patients who did and did not have additional chemotherapy, see Additional Chemotherapy Extends Survival in Relapsed Mesothelioma Patients, now available on the Surviving Mesothelioma website. Takuwa, T, et al, Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy”, April 24, 2017, International Journal of Clinical Oncology, Epub ahead of print, https://link.springer.com/article/10.1007/s10147-017-1126-x For more than a decade, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
News Article | May 8, 2017
More than 1,200 national and international surgeons, anesthesiologists and their teams have come to UAB to learn his techniques and the way in which he engages his teams to provide efficient, high-quality and patient-centered care. During his tenure at UAB, he developed a four-arm robotic approach to treat patients needing lung cancer excisions, removal of cancerous esophageal tumors and tumor resections within the thoracic region. His robotic techniques have reduced complications, increased survival and shortened hospital stays. In addition to his position at UAB, Cerfolio serves as the director of the American Association of Thoracic Surgery's Robotic Graham Fellowship, and has trained a large percentage of thoracic surgeons in the U.S. and abroad. "We are excited to welcome Dr. Cerfolio to lead our Clinical Thoracic Surgery Division," said Aubrey C. Galloway, MD, the Seymour Cohn Professor and chair of the Department of Cardiothoracic Surgery. "He has a proven track record of exceptional patient outcomes, and will strengthen our robust thoracic surgery and lung cancer programs with his extraordinary expertise in robotic thoracic surgery." According to the U.S. Centers for Disease Control and Prevention, more Americans die from lung cancer than any other type of cancer – approximately 155,000 annually. In 2013, the most recent year for statistics, more than 212,500 individuals were diagnosed with lung cancer – almost equally divided between men and women. At Perlmutter Cancer Center, Cerfolio will lead a new multidisciplinary lung cancer center, bolstered by nationally renowned surgeons, medical and radiation oncologists, radiologists, pulmonologists and other specialists. Some have long tenure at NYU Langone and others are newly-recruited clinical and investigative leaders – all committed to developing a program that rivals the very best in the country. "Lung cancer is an insidious disease that is difficult to treat, especially when it progresses to more advanced stages," said Benjamin G. Neel, MD, PhD, director of NYU Langone's Perlmutter Cancer Center. "Dr. Cerfolio will provide a new level of excellence to our rapidly expanding lung cancer program. Patients who turn to us can rest assured they will have access to the finest clinical care, the latest treatments and the most advanced cutting-edge research." Cerfolio earned both his undergraduate and medical degrees from the University of Rochester where he was a First Team Academic All-American baseball player and a Rhodes Scholar Candidate. He received his first two years of post-doctoral surgical training at The University of Connecticut St. Francis Hospital. After a year of urologic surgical training at Cornell and Memorial Sloan Kettering, he completed the last two years of his general surgical residency at the Mayo Clinic in Rochester, Minnesota, where he also completed a cardiothoracic surgical fellowship. In 2013, he received his MBA from the University of Tennessee. He joined UAB in 1996, where he served in numerous academic and clinical positions before being named Division Chief in Thoracic Surgery in 2002. He also serves as the chair of UAB's Business Intelligence Committee. Cerfolio has published over 150 original peer-reviewed articles, 40 book chapters, and has given over 400 lectures and presentations at major international and national scientific meetings. He also has been an invited visiting professor at hundreds of major academic institutions in more than 22 countries. In 2014, he authored his first book, Super Performing at Work and at Home: The Athleticism of Surgery and Life, and has recently completed his second book on leadership entitled, Inspire. "I'm honored to join NYU Langone and its Perlmutter Cancer Center, and to be asked to be part of a team that brings together all elements of lung cancer care to provide the very best to our patients, many of whom are in the fight of their lives," Cerfolio says. "We plan for innovative ways to serve patients in the New York tri-state and those all over the world." This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-lung-cancer-center-at-nyu-langone-welcomes-renowned-thoracic-surgeon-as-its-director-300452614.html
News Article | April 27, 2017
— The global market for radiation detection and monitoring is expected to be driven by the increasing demand from key end-users such as nuclear power plants and defense and military. The increasing construction of nuclear power plants in developing countries in APAC is expected to drive the market during the forecast period. Publisher's analysts forecast the global radiation detection and monitoring market to grow at a CAGR of 5.36% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global radiation detection and monitoring market for 2017-2021. To calculate the market size, the report considers the revenue generated from radiation detection and monitoring. The market is divided into the following segments based on geography: - Americas - APAC - EMEA Publisher's report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Get Sample of the Report at: http://www.reportsweb.com/inquiry&RW0001608771/sample . Market driver - Rising use of radiation in manufacturing industries - For a full, detailed list, view our report Market challenge - Difficulties in large area monitoring - For a full, detailed list, view our report Market trend - Growing nuclear power plants in APAC - For a full, detailed list, view our report PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Global radiation detection and monitoring market PART 06: Market segmentation by end-user PART 07: Market segmentation by product type PART 08: Geographical segmentation PART 09: Market drivers PART 10: Impact of drivers PART 11: Market challenges PART 12: Impact of drivers and challenges PART 13: Market trends PART 14: Vendor landscape PART 15: Key vendor analysis PART 16: Appendix For more information, please visit http://www.reportsweb.com/global-radiation-detection-and-monitoring-market-2017-2021
News Article | April 17, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Online Electronics Retailing Market 2017-2021" report to their offering. The global online electronics retailing market to grow at a CAGR of 14.31% during the period 2017-2021. The report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. One trend in market is cross-border e-commerce. As the global economic growth is transforming the world into a global marketplace, online merchants, card processors, and payment solution providers are learning how to collaborate with each other and overcome technical and business hurdles. Canada accounts for the highest share of online cross-border shoppers across the globe. Also, French cross-border shoppers purchase products from online retailers in Canada. Over three-fourths of the overall German online retailers in German-speaking countries such as Austria and Switzerland engage in cross-border e-commerce. France also accounts for the same percentage where shoppers and merchants engage in cross-border e-commerce with economies such as Belgium and Switzerland. For more information about this report visit http://www.researchandmarkets.com/research/fnd9jj/global_online
News Article | April 20, 2017
New Market Research Reports Title "Global Hybrid Operating Room Market To Reach Worth USD 9.7 Bn By 2022: Credence Research" Has Been Added to Credenceresearch.com Report Database. San Jose, CA, April 20, 2017 --( Browse the full report Hybrid Operating Room Market: Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/hybrid-operating-room-market Market Insights Hybrid operating rooms are extremely complex working environments where a large team of surgeons, interventionalists, nurses, anesthesiologists, and technicians need to work seamlessly together. A hybrid OR (Operating Room) is an alternative to conventional OR equipped with advanced medical imaging systems and devices supporting high quality interventional imaging and minimally invasive surgeries. North America held the largest regional market, accounting for the market share of over 37.3% in 2015, and is anticipated to dominate the global hybrid operating room market during the forecast period of 2016 to 2022. Rising number of hybrid operating room facilities and higher acceptance of technology are the key factors driving the North America hybrid operating room market. Asia Pacific is expected to grow at a highest growth rate during the focus period, due to rising medical tourism in the region, growing medical investments and healthcare infrastructure in Asia Pacific. Browse All Reports of This Category @ http://www.credenceresearch.com/industry/medical-devices-market Among the devices types, intraoperative diagnostic devices held the largest share in the global hybrid operating room market due to its wider application in the cardiovascular and neurosurgery. Moreover, rising minimally invasive surgeries would further enhance the application of intraoperative diagnostic devices driving the market further. The therapeutic application held the largest share in the global hybrid operating room market. The cardiovascular surgeries dominated the therapeutic application segment owing to the rise in the prevalence of cardiovascular diseases worldwide. The diagnostic imaging is anticipated to exhibit fastest growth rate in the hybrid operating room market. Rising number of minimally invasive surgery and robotic surgery to drive the diagnostic imaging market. Hospitals held the largest share in the end user segment of the global hybrid operating room market. Rising number of hospitals coming up with hybrid operating room is the major factor driving the hybrid operating room market. Clinics are expected to be the fastest growing end user segment in the global hybrid operating room market. Blog URL - http://www.mobilecomputingtoday.co.uk/4193/global-hybrid-operating-room-market-reach-worth-usd-9-7-2022-rising-demand-minimally-invasive-surgery-drive-market-credence-research/ About Credence Research: Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task. For More Information, Visit: Credence Research Media Contact Company Name: Credence Research Contact Person: Chris Smith, Designation: Global Sales Manager Phone: 1-800-361-8290 Address: 105 N 1st ST #429, San Jose, CA 95103 E-mail: email@example.com San Jose, CA, April 20, 2017 --( PR.com )-- According to the latest report published by Credence Research, Inc. “Hybrid Operating Room Market – (Device Type - Operating Tables, Lighting Systems, Surgical Beams, Surgical Imaging Displays, Intraoperative Diagnostic Devices and Operating Room Communication Systems; Application Type - Therapeutic: Cardiovascular Surgeries, Neurosurgery, Thoracic Surgery, Biopsy, Orthopedic Surgeries, Laparoscopic Surgeries, Emergency Care And Other Surgeries, Diagnostics: Fluoroscopy, Digital Subtraction Angiography, And 3D C-Arm Computer Tomography; End User – Hospitals, Clinics, Medical Research Institute And Ambulatory Surgical Centers) :Market Growth, Future Prospects and Competitive Analysis, 2016-2022,” the market was valued at USD 3.4 Bn in 2015, and is expected to reach USD 9.7 Bn by 2022, expanding at a CAGR of 16.1% from 2016 to 2022.Browse the full report Hybrid Operating Room Market: Growth, Future Prospects and Competitive Analysis, 2016-2022 report at http://www.credenceresearch.com/report/hybrid-operating-room-marketMarket InsightsHybrid operating rooms are extremely complex working environments where a large team of surgeons, interventionalists, nurses, anesthesiologists, and technicians need to work seamlessly together. A hybrid OR (Operating Room) is an alternative to conventional OR equipped with advanced medical imaging systems and devices supporting high quality interventional imaging and minimally invasive surgeries. North America held the largest regional market, accounting for the market share of over 37.3% in 2015, and is anticipated to dominate the global hybrid operating room market during the forecast period of 2016 to 2022. Rising number of hybrid operating room facilities and higher acceptance of technology are the key factors driving the North America hybrid operating room market. Asia Pacific is expected to grow at a highest growth rate during the focus period, due to rising medical tourism in the region, growing medical investments and healthcare infrastructure in Asia Pacific.Browse All Reports of This Category @ http://www.credenceresearch.com/industry/medical-devices-marketAmong the devices types, intraoperative diagnostic devices held the largest share in the global hybrid operating room market due to its wider application in the cardiovascular and neurosurgery. Moreover, rising minimally invasive surgeries would further enhance the application of intraoperative diagnostic devices driving the market further.The therapeutic application held the largest share in the global hybrid operating room market. The cardiovascular surgeries dominated the therapeutic application segment owing to the rise in the prevalence of cardiovascular diseases worldwide. The diagnostic imaging is anticipated to exhibit fastest growth rate in the hybrid operating room market. Rising number of minimally invasive surgery and robotic surgery to drive the diagnostic imaging market.Hospitals held the largest share in the end user segment of the global hybrid operating room market. Rising number of hospitals coming up with hybrid operating room is the major factor driving the hybrid operating room market. Clinics are expected to be the fastest growing end user segment in the global hybrid operating room market.Blog URL - http://www.mobilecomputingtoday.co.uk/4193/global-hybrid-operating-room-market-reach-worth-usd-9-7-2022-rising-demand-minimally-invasive-surgery-drive-market-credence-research/About Credence Research:Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.For More Information, Visit: Credence ResearchMedia ContactCompany Name: Credence ResearchContact Person: Chris Smith,Designation: Global Sales ManagerPhone: 1-800-361-8290Address: 105 N 1st ST #429, San Jose,CA 95103E-mail: firstname.lastname@example.org Click here to view the list of recent Press Releases from Credence Research
News Article | May 8, 2017
PHILADELPHIA - A newly identified molecular chain of events in a mouse model of prostate cancer highlights novel targets to treat it and other cancers. A team led by Marcelo Kazanietz, PhD, a professor of Systems Pharmacology and Translational Therapeutics, published in Cell Reports that the overexpression of a protein called PKCε with the loss of the tumor suppressor Pten causes the progression of prostate cancer. This deadly combination produces an uptick in the levels of the cancer-promoting molecule CXCL13. When the team purposely disrupted CXCL13, or CXCR5, the cell-surface receptor it attaches to, the metastatic and tumor-forming characteristics of the mouse prostate cancer cells were impaired. "In addition to providing evidence for a vicious cancer cycle driven by PKCε, our studies identified a compelling rationale for blocking the CXCL13-CXCR5 molecules as a new cancer treatment," Kazanietz said. He and colleagues plan to identify compounds to block CXCR5 or CXCL13 with potential to be developed as anti-cancer agents. The researchers also suggested that CXCL13 levels in blood could be used as a biomarker to measure the precise state of prostate cancer progression in a patient. The team's next step will be to interfere with CXCR5/CXCL13 signals not only from the cancer cells but also from other cells in the tumor microenvironment that contribute to cancer growth. Pulmonologists and oncologists have also observed that PKCε is overexpressed in lung cancer patients, but they do not fully understand its exact molecular consequences. In general, a high level of PKCε is associated with a poor prognosis. "We are in the midst of extending these findings to lung cancer," said Kazanietz, who is collaborating with Penn Medicine researchers David Feldser, PhD, an assistant professor of Cancer Biology, Steven M. Albelda, MD, a professor of Pulmonary, Allergy and Critical Care, and Evgeniy Eruslanov, PhD, a research assistant professor of Thoracic Surgery. This research was funded in part by the National Institutes of Health (R01-CA089202, R01-CA189765, R01-CA196232), the Department of Defense (PC130641, W81XWH-12-1-0009). Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year. The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.
News Article | February 21, 2017
ALAMEDA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced the receipt of $2,031,250 through the early exercise of 625,000 common stock purchase warrants. Each warrant was exercised to purchase one share of common stock for $3.25 per share. The warrants were issued during August 2016 through a private placement of 3,246,153 units, with each unit consisting of one share of common stock and one warrant to purchase one share of common stock. The exercise transactions were negotiated with certain warrant holders as a means of raising additional near term working capital. In consideration for the early exercise of the warrants, one warrant holder received one new warrant with an exercise price of $3.25 for every two warrants exercised, while the other warrant holders received one new warrant with an exercise price of $5.50 for each warrant exercised. Following the exercise of the warrants, there are 29,361,616 shares of common stock outstanding and an aggregate of 3,033,653 warrants outstanding, including both warrants issued during August 2016 and the new warrants, with exercise prices ranging from $3.25 to $5.50. The proceeds from the early warrant exercise will be used for general working capital purposes to strengthen OncoCyte’s balance sheet, which reflected cash on hand of approximately $10.2 million as of December 31, 2016. “The early exercise of warrants by some of our largest shareholders provides a strong vote of confidence in OncoCyte and our progress towards the development of our innovative, non-invasive tests for the early detection of cancer. The capital provided to us increases our resources as we prepare for CLIA certification of our laboratory and the hiring of our launch team,” said William Annett, President & CEO. “The warrant exercise and commensurate purchase of shares results in BioTime, Inc.’s ownership of our company falling below 50%. This is an important step in OncoCyte’s evolution into an independent company.” OncoCyte has completed sample collection for the 300-patient study of its lung cancer diagnostic test and now has all of the benign and malignant samples necessary to complete the study. Processing of the samples has been completed and an analysis of the results is underway. The Company expects to complete the study and announce the results in March. As the analysis of the samples is carried out, OncoCyte is continuing to work on completing the steps necessary to obtain CLIA certification of a diagnostic laboratory. OncoCyte plans to apply for CLIA certification of the lab subsequent to the completion of its current lung cancer test study. After CLIA certification of the laboratory, OncoCyte will conduct a clinical validation study of its lung cancer diagnostic test using the finalized processing algorithm and operational procedures on a new set of a minimum of 300 blinded patient blood samples. “Completion of sample collection, processing the samples and analyzing the results are three key elements in developing our lung cancer diagnostics test,” said Mr. Annett. “If the results of the 300 sample study are favorable, our next steps will be to begin the final clinical validation study and finalize our commercialization plans.” The development of the test builds on research that began a decade ago at the Wistar Institute and has proceeded at OncoCyte and in collaboration with several key opinion leaders in the field of lung cancer diagnosis. OncoCyte recently announced that its abstract on interim data from its current lung cancer diagnostic test study has been selected for presentation in a poster discussion session at the 2017 American Thoracic Society (ATS) International Conference in Washington, D.C. The discussion will be led by Dr. Anil Vachani, an Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center. The analysis “Multi-Gene Classifier for the Diagnosis of Benign Versus Malignant Pulmonary Nodules” will be discussed in the “Pulmonary Nodules and Thoracic Surgery: Working Across the Aisle” session to take place at 2:15 p.m. on Monday, May 22nd. OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncocyte.com. This press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) are forward-looking statements. These statements include those pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients ’use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in “Risk Factors” found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as may be required by law.
News Article | February 16, 2017
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Robotic Pharmacy Prescription Dispensing Systems Market 2017-2021" report to their offering. The global robotic pharmacy prescription systems market to grow at a CAGR of 5.16% during the period 2017-2021. The report, Global Thoracic Surgery Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Vendors are providing technicians with operational guidance and personalized technical support 24/7. In addition, with the support package, vendors are offering automated systems updated with the latest software and drug database for both new installation and leased systems. Therefore, vendors are offering maintenance and post-purchase services to end-users to retain their customer base and remain competitive in the market. According to the report, the automation of prescription dispensing is becoming increasingly essential because of the deficit in the quality staff in pharmacies. This has led to increased adoption of pharmacy automation systems to reduce dispensing errors, improvement in the dispensing process, optimization of space utilization in pharmacies, and delivery of more patient-centric services. For more information about this report visit http://www.researchandmarkets.com/research/8lk9nm/global_robotic
News Article | February 20, 2017
— Governance, risk, and compliance constitute three essential dimensions for an organization as they assist in addressing the business objectives. The management of a company implements structural policies and reforms to ensure corporate governance in an organization. The risk management policies identify and manage different risks, including operational risks, financial risks, and fraud. Compliance encompasses policies, procedures, and adherence to rules and regulations framed by regulatory bodies in a given region. Publisher's analysts forecast the global GRC platform market to grow at a CAGR of 13.51% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global GRC platform market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of GRC platform worldwide. The market is divided into the following segments based on geography: -Americas -APAC -EMEA Publisher's report, Global Thoracic Surgery Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Get Sample of the Report at: http://www.reportsweb.com/inquiry&RW0001502498/sample . Market driver -Increased need to comply with regulatory requirements -For a full, detailed list, view our report Market challenge -System integration issues for cloud-based and on-premises GRC solutions -For a full, detailed list, view our report Market trend -Rise of cloud-based e-discovery solution market -For a full, detailed list, view our report PART 01: Executive summary PART 02: Scope of the report PART 03: Market research methodology PART 04: Introduction PART 05: Economic overview of market PART 06: Market landscape PART 07: Market segmentation by deployment models PART 08: Geographical segmentation PART 09: Market drivers PART 10: Impact of drivers PART 11: Market challenges PART 12: Impact of drivers and challenges PART 13: Market trends PART 14: Five forces analysis PART 15: Vendor landscape PART 16: Key vendor profiles PART 17: Other prominent vendors PART 18: Appendix For more information, please visit http://www.reportsweb.com/global-governance-risk-and-compliance-platform-market-2017-2021